HS
TCRT icon

HighVista Strategies’s Alaunos Therapeutics TCRT Stock Holding History

HighVista Strategies’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-126
Closed -$46K – 115
2020
Q1 		$46K Buy
126
+35
+38% +$18.1K 0.04% 49
2019
Q4 		$65K Hold
91
– – 0.05% 115
2019
Q3 		$59K Buy
+91
New +$72.2K 0.04% 109

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighVista Strategies's TCRT Position: Q2 2020 in Review

HighVista Strategies sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 126 shares — an estimated $46K sold.

HighVista Strategies first reported a position in TCRT in Q3 2019 and held it in 3 quarters. The position peaked at $65K in Q4 2019. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

  • HighVista Strategies reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
  • HighVista Strategies sold 126 Alaunos Therapeutics shares in Q2 2020, an estimated $46K.
  • HighVista Strategies first reported a position in Alaunos Therapeutics in Q3 2019 and held it in 3 quarters.
  • HighVista Strategies's Alaunos Therapeutics position peaked at $65K in Q4 2019.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on HighVista Strategies's 13F filing for Q2 2020, filed 14 Aug 2020.